Compared with placebo, vutrisiran was shown to reduce serum levels of NT-proBNP, improve some echocardiographic parameters, and improve scintigraphy tracer uptake in ATTRv patients with polyneuropathy. This evidence concerns the gene NPPB and polyneuropathy.